A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Masitinib (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms MAXIMS
- Sponsors AB Science
Most Recent Events
- 10 Oct 2024 According to AB Science media release, data from the study were presented at the ECTRIMS 2024 conference
- 08 Mar 2024 According to AB Science media release, this trial authorized by FDA and key European countries with initiation expected in 2024.
- 21 Nov 2023 This trial has been suspended in Norway, according to European Clinical Trials Database record.